Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

In this case report we present a patient with displaced donor graft after DSAEK and associated peripheral corneal edema that resolved without any further intervention three months postoperatively.